OBJECTIVE： To explore the efficacy of tripterygium glycosides for children with purpuric nephritis and its effects on related indicators. METHODS： 77 children with purpuric nephritis were randomly divided into control group （38 cases） and observation group （38 cases） . Control group received anti-allergy， anti-platelet， nutritional support and other conventional treatment； observation group was additionally given Tripterygium glycosides tablet 1 mg/（kg·d） for 3 times， taking after a meal. All patients were treated for 12 weeks. Clinical efficacy， IL-10， chemokine 9（CXCL9）， transforming growth factor-β1（TGF-β1）， metal matrix protease-9（MMP-9）， IgA， IgG， IgM before and after treatment in 2 groups were observed， the correlation of IL-10， CXCL9， TGF-β1 and IgA in observation group was analyzed， and the incidence of adverse reactions was recorded. RESULTS： The total effective rate in observation group was significantly higher than control group， the incidence of adverse reactions was significantly lower than control group， with statistical significances （P＜0.05）. Before treatment， there were no significant differences in the IL-10， CXCL9， TGF-β1，MMP-9， IgA， IgG and IgM in 2 groups （P＞0.05）. After treatment， IL-10 in 2 groups was significantly higher than before， and observation group was higher than control group， CXCL9， TGF-β1， MMP-9， IgA and IgG were significantly lower than before， CXCL9， TGF-β1 and IgA in observation group were lower than control group， with statistical significances （P＜0.05）， while there were no significant differences in IgG， MMP-9 and IgM before and after treatment in 2 groups （P＞0.05）. IL-10 was negatively correlated with IgA （r＝－0.636，P＜0.001）， CXCL-9 was positively correlated with IgA （r＝0.434，P＜0.001）， and TGF-β1 was positively correlated with IgA （r＝0.350，P＜0.001）. CONCLUSIONS： Based on conventional treatment， tripterygium glycosides has significant efficacy for purpuric nephritis， can improve inflammation and immune factor levels， with good safety.